Background
Methods
Study patients and treatment regimens
HCV sequence alignment and primer design
Polymerase chain reaction (PCR)
Data analysis and statistics
Results
Response to PEG-IFN/RBV therapy
Variable | R | NR | P-value |
---|---|---|---|
Age (yrs.) | |||
Mean ± SD* | 45.82 ± 14.67 | 49.19 ± 15.26 | 0.152c
|
Median (25th-75th)¶
| 48.00(35.50-57.00) | 52.50(44.50-59.00) | 0.095a
|
Sex
§
| |||
Male count (%) | 21(37.5%) | 22(37.3%) | 0.862b
|
Female count (%) | 35(62.5%) | 37(62.7%) | |
Weight ( kg)
*
| 74.54 ± 28.01 | 76.04 ± 18.81 | 0.609c
|
Bil (mg/dL)
*
| 10.54 ± 4.89 | 12.09 ±6.83 | 0.42c
|
ALT (IU/L)
*
| 76.59 ±57.5 | 82.2 ± 76.2 | 0.424c
|
AST (IU/L)
*
| 59.27 ± 43.37 | 53.63 ± 55.81 | 0.14c
|
ALP (IU/L)
*
| 98.4 ± 67.8 | 116.13 ± 60.98 | 0.538c
|
AFP (ng/mL)
*
| 8.22 ±17.12 | 7.76 ± 18.18.47 | 0.904c
|
HCV load log10
¶
| 5.74(5.21-6.40) | 5.88(5.15-6.48) | 0.837a
|
Median (25th-75th)¶
| |||
Stage
§
| |||
≤2 count (%) | 24(77.4%) | 21(63.6%) | 0.227b
|
≥3 count (%) | 7(22.6%) | 12(36.4%) | |
Grade
§
| |||
≥1 count (%) | 8(25%) | 8(22.2%) | 0.788b
|
3 count (%) | 24(75%) | 28(77.8%) | |
Genotypes
§
| |||
4a (%) | 39(58%) | 28(42%) | 0.02b
|
4d (%) | 17(35%) | 31(65%) |
Genotype | Response | No. of sequence | No. of ref seq | Mean genetic distance within groups | Mean genetic distance between groups |
---|---|---|---|---|---|
4a
| SVR* | 39 | 1 | 0.0221 | 0.027 |
Non-SVR | 28 | 1 | 0.0225 | ||
4d
| SVR | 17 | 1 | 0.0173 | 0.016 |
Non-SVR | 31 | 1 | 0.0133 |